LSL Pharma Group Inc. (TSXV:LSL)
Canada · Delayed Price · Currency is CAD 0.3700
-0.0050 (-1.33%)
Sep 10, 2025, 3:00 PM EDT
LSL Pharma Group Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2020 |
| 23.24 | 17.75 | 10.03 | 8.21 | 8.77 | 10.05 | Upgrade | |
Revenue Growth (YoY) | 62.22% | 76.98% | 22.08% | -6.35% | -12.70% | 108.32% | Upgrade |
Cost of Revenue | 16.4 | 12.4 | 8.38 | 10.39 | 6.89 | 6.85 | Upgrade |
Gross Profit | 6.83 | 5.35 | 1.65 | -2.17 | 1.88 | 3.2 | Upgrade |
Selling, General & Admin | 5.66 | 4.52 | 3.64 | 3.92 | 2.59 | 1.52 | Upgrade |
Research & Development | - | - | - | 0.67 | - | - | Upgrade |
Operating Expenses | 5.73 | 4.94 | 5.76 | 4.59 | 2.59 | 1.52 | Upgrade |
Operating Income | 1.11 | 0.41 | -4.12 | -6.76 | -0.71 | 1.68 | Upgrade |
Interest Expense | -2.18 | -1.9 | -1.76 | -1.39 | -1.71 | -1.26 | Upgrade |
Other Non Operating Income (Expenses) | -0.13 | - | -0.05 | -0.15 | - | -0.17 | Upgrade |
EBT Excluding Unusual Items | -1.21 | -1.5 | -5.92 | -8.29 | -2.41 | 0.25 | Upgrade |
Merger & Restructuring Charges | - | - | -2.55 | -0.43 | - | - | Upgrade |
Other Unusual Items | 4.82 | 4.86 | - | 0.66 | 0.78 | 0.57 | Upgrade |
Pretax Income | 3.62 | 3.37 | -8.47 | -8.06 | -1.63 | 0.82 | Upgrade |
Income Tax Expense | 0.05 | 0.05 | - | - | 0.15 | 0.21 | Upgrade |
Net Income | 3.57 | 3.32 | -8.47 | -8.06 | -1.78 | 0.61 | Upgrade |
Net Income to Common | 3.57 | 3.32 | -8.47 | -8.06 | -1.78 | 0.61 | Upgrade |
Net Income Growth | - | - | - | - | - | 592.98% | Upgrade |
Shares Outstanding (Basic) | 116 | 105 | 80 | 66 | 59 | 55 | Upgrade |
Shares Outstanding (Diluted) | 116 | 105 | 80 | 66 | 59 | 55 | Upgrade |
Shares Change (YoY) | 30.07% | 31.18% | 20.94% | 11.78% | 8.34% | 14.88% | Upgrade |
EPS (Basic) | 0.03 | 0.03 | -0.11 | -0.12 | -0.03 | 0.01 | Upgrade |
EPS (Diluted) | 0.03 | 0.03 | -0.11 | -0.12 | -0.03 | 0.01 | Upgrade |
EPS Growth | - | - | - | - | - | 503.48% | Upgrade |
Free Cash Flow | 0.43 | -3.25 | -7.73 | -4.16 | -2 | -4.47 | Upgrade |
Free Cash Flow Per Share | 0.00 | -0.03 | -0.10 | -0.06 | -0.03 | -0.08 | Upgrade |
Gross Margin | 29.41% | 30.13% | 16.40% | -26.44% | 21.47% | 31.83% | Upgrade |
Operating Margin | 4.76% | 2.29% | -41.05% | -82.26% | -8.07% | 16.74% | Upgrade |
Profit Margin | 15.36% | 18.69% | -84.48% | -98.15% | -20.26% | 6.07% | Upgrade |
Free Cash Flow Margin | 1.85% | -18.31% | -77.04% | -50.66% | -22.80% | -44.47% | Upgrade |
EBITDA | 2.9 | 1.71 | -3.21 | -5.97 | 0.1 | 2.51 | Upgrade |
EBITDA Margin | 12.49% | 9.61% | -32.03% | -72.67% | 1.17% | 25.01% | Upgrade |
D&A For EBITDA | 1.8 | 1.3 | 0.9 | 0.79 | 0.81 | 0.83 | Upgrade |
EBIT | 1.11 | 0.41 | -4.12 | -6.76 | -0.71 | 1.68 | Upgrade |
EBIT Margin | 4.76% | 2.29% | -41.05% | -82.26% | -8.07% | 16.74% | Upgrade |
Effective Tax Rate | 1.38% | 1.49% | - | - | - | 25.92% | Upgrade |
Revenue as Reported | 23.24 | 17.75 | 10.03 | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.